Abstract:Cancer stem cells have been isolated from a number of human tumours. The latest example is a subpopulation of human malignant melanoma initiating cells, identified by their expression of the chemoresistance mediator ABCB5. The size of the ABCB5+ subpopulations correlates with clinical disease progression in patients with melanomas, and preliminary evidence also suggests that these melanoma stem cells can be specifically targeted with antibodies against ABCB5. This offers a potential therapeutic strategy against melanomas, and the study of cells of this type could help answer important questions in cancer biology. The hybrid melanoma cell shown on the cover, depicted as a merged, computer-enhanced fluorescent microscopy image, arose in vivo in a human tumour xenograft through fusion of an ABCB5+ melanoma stem cell with a more differentiated, ABCB5− tumour cell. Nuclei are marked by genetically encoded red (DsRed) and green (EYFP) fluorescent labels, respectively. The isolation of tumour-initiating cells from human melanomas is reported, with preliminary evidence suggesting that these melanoma stem cells can be specifically targeted with antibodies targeted against ABCB5, which offers a potential therapeutic strategy against melanomas. Tumour-initiating cells capable of self-renewal and differentiation, which are responsible for tumour growth, have been identified in human haematological malignancies1,2 and solid cancers3,4,5,6. If such minority populations are associated with tumour progression in human patients, specific targeting of tumour-initiating cells could be a strategy to eradicate cancers currently resistant to systemic therapy. Here we identify a subpopulation enriched for human malignant-melanoma-initiating cells (MMIC) defined by expression of the chemoresistance mediator ABCB5 (refs 7, 8) and show that specific targeting of this tumorigenic minority population inhibits tumour growth. ABCB5+ tumour cells detected in human melanoma patients show a primitive molecular phenotype and correlate with clinical melanoma progression. In serial human-to-mouse xenotransplantation experiments, ABCB5+ melanoma cells possess greater tumorigenic capacity than ABCB5- bulk populations and re-establish clinical tumour heterogeneity. In vivo genetic lineage tracking demonstrates a specific capacity of ABCB5+ subpopulations for self-renewal and differentiation, because ABCB5+ cancer cells generate both ABCB5+ and ABCB5- progeny, whereas ABCB5- tumour populations give rise, at lower rates, exclusively to ABCB5-cells. In an initial proof-of-principle analysis, designed to test the hypothesis that MMIC are also required for growth of established tumours, systemic administration of a monoclonal antibody directed at ABCB5, shown to be capable of inducing antibody-dependent cell-mediated cytotoxicity in ABCB5+ MMIC, exerted tumour-inhibitory effects. Identification of tumour-initiating cells with enhanced abundance in more advanced disease but susceptibility to specific targeting through a defining chemoresistance determinant has important implications for cancer therapy.

Epigenetic and Stem Cell Biomarkers in Experimental Melanoma Metastases

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

Effect Of Melanoma Stem Cells On Melanoma Metastasis

Effect of Melanoma Stem Cells on Melanoma Metastasis (Review)

Network-Based Identification of Altered Stem Cell Pluripotency and Calcium Signaling Pathways in Metastatic Melanoma

Identifying Metabolomic Features That Predict Metastasis of Melanoma from a Primary Site

Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers

Discovery and Validation of a Metastasis-Related Prognostic and Diagnostic Biomarker for Melanoma Based on Single Cell and Gene Expression Datasets.

Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers

Melanoma stem cell markers and targeted therapies: awareness and pertinence

Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis

Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care

The Abundance of Metabolites Related to Protein Methylation Correlates with the Metastatic Capacity of Human Melanoma Xenografts

Melanoma progression and prognostic models drawn from single-cell, spatial maps of benign and malignant tumors

5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies

Cancer stem cell property and gene signature in bone-metastatic Breast Cancer cells

The roles of cancer stem cells and therapeutic implications in melanoma

Identification of Cells Initiating Human Melanomas.

Abstract 5530: Metastasis founder cells activate immunsuppression early in human metastatic colonization